Lipid-modifying effects of nutraceuticals: An evidence-based approach

Nutrition

Volumn 32, Issue 11-12, 2016, Pages 1179-1192

  Sahebkar, Amirhossein ^a,b   Serban, Maria Corina ^c   Gluba Brzózka, Anna ^d   Mikhailidis, Dimitri P ^e   Cicero, Arrigo F ^f   Rysz, Jacek ^d   Banach, Maciej ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherogenic dyslipidemia; Functional foods; Lipids; Nutraceuticals

Indexed keywords

BERBERINE; CHITOSAN; CHOLESTEROL; CHOLESTIN; CONJUGATED LINOLEIC ACID; FISH OIL; MANNAN; NUTRACEUTICAL; PROBIOTIC AGENT; RESVERATROL; TRIACYLGLYCEROL; ANTHOCYANIN; ANTILIPEMIC AGENT; BIOLOGICAL PRODUCT; EDIBLE OIL; LIPID; PHYTOSTEROL; STILBENE DERIVATIVE;

ABSORPTION; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DIETARY INTAKE; EVIDENCE BASED MEDICINE; FOOD INTAKE; GARLIC; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LINSEED; LIPID ANALYSIS; NUTRITION EDUCATION; PHYTOCHEMISTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SPIRULINA; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TEA; TRIACYLGLYCEROL BLOOD LEVEL; VEGETABLE; BLOOD; DIET THERAPY; DIETARY FIBER; DIETARY SUPPLEMENT; DYSLIPIDEMIAS; HIBISCUS; THERAPEUTIC USE;

ANTHOCYANINS; BERBERINE; BIOLOGICAL PRODUCTS; DIETARY FATS, UNSATURATED; DIETARY FIBER; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; GARLIC; HIBISCUS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; PHYTOSTEROLS; PROBIOTICS; STILBENES;

EID: 84988434112     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2016.04.007     Document Type: Review

References (223)

1. [1] Mannarino, M.R., Ministrini, S., Pirro, M., Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med 25 (2014), 592–599.
2. [2] Chen, G., Wang, H., Zhang, X., Yang, S.T., Nutraceuticals and functional foods in the management of hyperlipidemia. Crit Rev Food Sci Nutr 54 (2014), 1180–1201.
3. [3] Sahebkar, A., Watts, G.F., Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes Obes Metab 16 (2014), 780–792.
4. [4] Sahebkar, A., Chew, G.T., Watts, G.F., New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 15 (2014), 493–503.
5. [5] Banach, M., Serban, C., Aronow, W.S., Rysz, J., Dragan, S., Lerma, E.V., et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol 46 (2014), 947–961.
6. [6] Sahebkar, A., Chew, G.T., Watts, G.F., Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 56 (2014), 47–66.
7. [7] Sahebkar, A., Watts, G.F., New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 35 (2013), 1082–1098.
8. [8] Sahebkar, A., Watts, G.F., New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?. Cardiovasc Drugs Ther 27 (2013), 559–567.
9. [9] Fruchart, J.C., Sacks, F., Hermans, M.P., Assmann, G., Brown, W.V., Ceska, R., et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102 (2008), 1K–34K.
10. [10] Hermans, M.P., Castro Cabezas, M., Strandberg, T., Ferrières, J., Feely, J., Elisaf, M., et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 26 (2009), 445–454.
11. [11] Leiter, L., Lundman, P., da Silva, P., Drexel, H., Jünger, C., Gitt, A., Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 28 (2011), 1343–1351.
12. [12] Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D.P., Rizzo, M., The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 19 (2013), 3124–3131.
13. [13] Toth, P.P., Barylski, M., Nikolic, D., Rizzo, M., Montalto, G., Banach, M., Should low high-density lipoprotein cholesterol (HDL-C) be treated?. Best Pract Res Clin Endocrinol Metab 28 (2014), 353–368.
14. [14] Rizzo, M., Barylski, M., Rizvi, A.A., Montalto, G., Mikhailidis, D.P., Banach, M., Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. Curr Pharm Des 19 (2013), 3858–3868.
15. [15] Scicchitano, P., Cameli, M., Maiello, M., Modesti, P.A., Muiesan, M.L., Novo, S., et al. Nutraceuticals and dyslipidaemia: beyond the common therapeutics. J Funct Foods 6 (2014), 11–32.
16. [16] Houston, M., The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hyertens (Greenwich) 14 (2012), 121–132.
17. [17] Banach, M., Aronow, W.S., Serban, C., Sahabkar, A., Rysz, J., Voroneanu, L., et al. Lipids, blood pressure and kidney update 2014. Pharm Res 95–6 (2015), 111–125.
18. [18] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285, 2001, 2486.
19. [19] Catapano, A.L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.R., Wiklund, O., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217 (2011), 1–44.
20. [20] Cicero, A.F., Ferroni, A., Ertek, S., Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf 11 (2012), 753–766.
21. [21] Badimon, L., Vilahur, G., Padro, T., Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther 28 (2010), 202–215.
22. [22] Garcia-Rios, A., Delgado-Lista, J., Alcala-Diaz, J.F., Lopez-Miranda, J., Perez-Martinez, P., Nutraceuticals and coronary heart disease. Curr Opin Cardiol 28 (2013), 475–482.
23. [23] Wu, T., Fu, J., Yang, Y., Zhang, L., Han, J., The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac J Clin Nutr, 18, 2009, 179.
24. [24] Dong, H., Zhao, Y., Zhao, L., Lu, F., The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 79 (2013), 437–446.
25. [25] Li, Y., Jiang, L., Jia, Z., Xin, W., Yang, S., Yang, Q., et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One, 9, 2014, e98611.
26. [26] Sahebkar, A., Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 71 (2013), 822–835.
27. [27] Sahebkar, A., A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr 33 (2014), 406–414.
28. [28] Pan, A., Yu, D., Demark-Wahnefried, W., Franco, O.H., Lin, X., Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr 90 (2009), 288–297.
29. [29] Ried, K., Toben, C., Fakler, P., Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev 71 (2013), 282–299.
30. [30] Wallace, T.C., Slavin, M., Frankenfeld, C.L., Systematic review of anthocyanins and markers of cardiovascular disease. Nutrients, 8, 2016, 32.
31. [31] Serban, C., Sahebkar, A., Ursoniu, S., Dragan, S., Andrica, F., Banach, M., A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations. Clin Nutr 35 (2016), 842–851.
32. [32] Aziz, Z., Wong, S.Y., Chong, N.J., Effects of Hibiscus sabdariffa L. on serum lipids: a systematic review and meta-analysis. J Ethnopharmacol 150 (2013), 442–450.
33. [33] Onakpoya, I., Spencer, E., Heneghan, C., Thompson, M., The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 24 (2014), 823–836.
34. [34] Zhu, W., Dong, C., Du, H., Zhang, H., Chen, J., Hu, X., et al. Effects of fish oil on serum lipid profile in dialysis patients: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis, 13, 2014, 127.
35. [35] Derakhshande-Rishehri, S.M., Mansourian, M., Kelishadi, R., Heidari-Beni, M., Association of foods enriched in conjugated linoleic acid (CLA) and CLA supplements with lipid profile in human studies: a systematic review and meta-analysis. Public Health Nutr 18 (2015), 2041–2054.
36. [36] Guo, Z., Liu, X.M., Zhang, Q.X., Shen, Z., Tian, F.W., Zhang, H., et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis 21 (2011), 844–850.
37. [37] Ha, V., Sievenpiper, J.L., de Souza, R.J., Jayalath, V.H., Mirrahimi, A., Agarwal, A., et al. Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials. CMAJ 186 (2014), E252–E262.
38. [38] Baker, W.L., Tercius, A., Anglade, M., White, C.M., Coleman, C.I., A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab 55 (2008), 368–374.
39. [39] Chua, M., Baldwin, T.C., Hocking, T.J., Chan, K., Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol 128 (2010), 268–278.
40. [40] AbuMweis, S.S., Jew, S., Ames, N.P., Beta-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 64 (2010), 1472–1480.
41. [41] Klingberg, S., Andersson, H., Mulligan, A., Bhaniani, A., Welch, A., Bingham, S., et al. Food sources of plant sterols in the EPIC Norfolk population. Eur J Clin Nutr 62 (2007), 695–703.
42. [42] Valsta, L., Lemstrom, A., Ovaskainen, M., Lampi, A., Toivo, J., Korhonen, T., et al. Estimation of plant sterol and cholesterol intake in Finland: quality of new values and their effect on intake. Br J Nutr 92 (2004), 671–678.
43. [43] Klingberg, S., Ellegård, L., Johansson, I., Hallmans, G., Weinehall, L., Andersson, H., et al. Inverse relation between dietary intake of naturally occurring plant sterols and serum cholesterol in northern Sweden. Am J Clin Nutr 87 (2008), 993–1001.
44. [44] Sioen, I., Matthys, C., Huybrechts, I., Van Camp, J., De Henauw, S., Consumption of plant sterols in Belgium: estimated intakes and sources of naturally occurring plant sterols and β-carotene. Br J Nutr 105 (2011), 960–966.
45. [45] Jiménez-Escrig, A., Santos-Hidalgo, A.B., Saura-Calixto, F., Common sources and estimated intake of plant sterols in the Spanish diet. J Agric Food Chem 54 (2006), 3462–3471.
46. [46] Jenkins, D.J., Kendall, C.W., Popovich, D.G., Vidgen, E., Mehling, C.C., Vuksan, V., et al. Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function. Metabolism 50 (2001), 494–503.
47. [47] Racette, S.B., Spearie, C.A., Phillips, K.M., Lin, X., Ma, L., Ostlund, R.E. Jr., Phytosterol-deficient and high-phytosterol diets developed for controlled feeding studies. J Am Diet Assoc 109 (2009), 2043–2051.
48. [48] Gylling, H., Plat, J., Turley, S., Ginsberg, H.N., Ellegård, L., Jessup, W., et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 232 (2014), 346–360.
49. [49] Nissinen, M., Gylling, H., Vuoristo, M., Miettinen, T.A., Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion. Am J Physiol Gastrointest Liver Physiol 282 (2002), G1009–G1015.
50. [50] Smet, E.D., Mensink, R.P., Plat, J., Effects of plant sterols and stanols on intestinal cholesterol metabolism: suggested mechanisms from past to present. Mol Nutr Food Res 56 (2012), 1058–1072.
51. [51] Calandra, S., Tarugi, P., Speedy, H.E., Dean, A.F., Bertolini, S., Shoulders, C.C., Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. J Lipid Res 52 (2011), 1885–1926.
52. [52] Dragan, S., Serban, C., Banach, M., Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?. Curr Med Chem 21 (2014), 2927–2946.
53. [53] Musa-Veloso, K., Poon, T.H., Elliot, J.A., Chung, C., A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids 85 (2011), 9–28.
54. [54] Ras, R.T., Geleijnse, J.M., Trautwein, E.A., LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr 112 (2014), 214–219.
55. [55] Amir Shaghaghi, M., Abumweis, S.S., Jones, P.J., Cholesterol-lowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis. J Acad Nutr Diet 113 (2013), 1494–1503.
56. [56] Fransen, H.P., de Jong, N., Wolfs, M., Verhagen, H., Verschuren, W.M., Lütjohann, D., et al. Customary use of plant sterol and plant stanol enriched margarine is associated with changes in serum plant sterol and stanol concentrations in humans. J Nutr 137 (2007), 1301–1306.
57. [57] Assmann, G., Cullen, P., Erbey, J., Ramey, D.R., Kannenberg, F., Schulte, H., Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case–control analysis of the Prospective Cardiovascular Münster (PROCAM) study. Nutr Metab Cardiovasc Dis 16 (2006), 13–21.
58. [58] Silbernagel, G., Fauler, G., Hoffmann, M.M., Lutjohann, D., Winkelmann, B.R., Boehm, B.O., et al. The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality. J Lipid Res 51 (2010), 2384–2393.
59. [59] Tilvis, R.S., Miettinen, T.A., Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 43 (1986), 92–97.
60. [60] Plat, J., Beugels, I., Gijbels, M.J., de Winther, M.P., Mensink, R.P., Plant sterol or stanol esters retard lesion formation in LDL receptor-deficient mice independent of changes in serum plant sterols. J Lipid Res 47 (2006), 2762–2771.
61. [61] Silbernagel, G., Fauler, G., Renner, W., Landl, E.M., Hoffmann, M.M., Winkelmann, B.R., et al. The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J Lipid Res 50 (2009), 334–341.
62. [62] Párraga-Martínez, I., López-Torres-Hidalgo, J.D., del Campo-del Campo, J.M., Galdón-Blesa, M.P., Precioso-Yáñez, J.C., Rabanales-Sotos, J., et al. Long-term effects of plant stanols on the lipid profile of patients with hypercholesterolemia. A randomized clinical trial. Rev Esp Cardiol 68 (2015), 665–671.
63. [63] Vásquez-Trespalacios, E.M., Romero-Palacio, J., Efficacy of yogurt drink with added plant stanol esters (Benecol®, Colanta) in reducing total and LDL cholesterol in subjects with moderate hypercholesterolemia: a randomized placebo-controlled crossover trial NCT01461798. Lipids Health Dis, 13, 2014, 125.
64. [64] Gupta, S., Singh, N., Jaggi, A.S., Alkaloids as aldose reductase inhibitors, with special reference to berberine. J Altern Complement Med 20 (2014), 195–205.
65. [65] Yin, J., Zhang, H., Ye, J., Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 8, 2008, 99.
66. [66] Lee, S., Lim, H.J., Park, J.H., Lee, K.S., Jang, Y., Park, H.Y., Berberine-induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 362 (2007), 853–857.
67. [67] Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 (2004), 1344–1351.
68. [68] Cameron, J., Ranheim, T., Kulseth, M.A., Leren, T.P., Berge, K.E., Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 201 (2008), 266–273.
69. [69] Dragan, S., Serban, M.C., Banach, M., Proprotein convertase subtilisin/kexin 9 inhibitors an emerging lipid-lowering therapy?. J Cardiovasc Pharmacol Ther 20 (2015), 157–168.
70. [70] Banach, M., Rizzo, M., Obradovic, M., Montalto, G., Rysz, J., Mikhailidis, D.P., et al. PCSK9 inhibition-a novel mechanism to treat lipid disorders?. Curr Pharm Des 19 (2013), 3869–3877.
71. [71] Brusq, J.M., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47 (2006), 1281–1288.
72. [72] Kong, W.J., Wei, J., Zuo, Z.Y., Wang, Y.M., Song, D.Q., You, X.F., et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 57 (2008), 1029–1037.
73. [73] Xin, H., Wu, X., Li, Q., Yu, A., Zhong, M., Liu, Y., The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol 28 (2006), 25–30.
74. [74] Lin, H., Liu, T., Wu, C., Chi, C., Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. Br J Cancer, 81, 1999, 416.
75. [75] Vrzal, R., Zdařilová, A., Ulrichová, J., Bláha, L., Giesy, J.P., Dvořák, Z., Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4 IIE cells: biphasic effect on CYP1 A1. Biochem Pharmacol 70 (2005), 925–936.
76. [76] Affuso, F., Mercurio, V., Fazio, V., Fazio, S., Cardiovascular and metabolic effects of Berberine. World J Cardiol, 2, 2010, 71.
77. [77] Chan, E., Displacement of bilirubin from albumin by berberine. Biol Neonate 63 (1993), 201–208.
78. [78] Ma, J., Li, Y., Ye, Q., Li, J., Hua, Y., Ju, D., et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48 (2000), 5220–5225.
79. [79] Arunachalam, C., Narmadhapriya, D., Monascus fermented rice and its beneficial aspects: a new review. Asian J Pharm Clin Res 4 (2011), 29–31.
80. [80] Chen, C.H., Yang, J.C., Uang, Y.S., Lin, C.J., Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. Int J Pharm 444 (2013), 18–24.
81. [81] Heber, D., Yip, I., Ashley, J.M., Elashoff, D.A., Elashoff, R.M., Go, V.L., Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69 (1999), 231–236.
82. [82] Becker, D.J., Gordon, R.Y., Halbert, S.C., French, B., Morris, P.B., Rader, D.J., Red yeast rice for dyslipidemia in statin-intolerant patientsa randomized trial. Ann Intern Med 150 (2009), 830–839.
83. [83] Chung, V.C., Liu, S., Sit, R.W., Is red yeast rice capsule beneficial for treating dyslipidemia amongst statin-intolerant patients as compared to placebo?. Adv Integr Med 1 (2014), 151–152.
84. [84] Cicero, A.F., Brancaleoni, M., Laghi, L., Donati, F., Mino, M., Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med 13 (2005), 273–278.
85. [85] Keithley, J.K., Swanson, B., Sha, B.E., Zeller, J.M., Kessler, H.A., Smith, K.Y., A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition 18 (2002), 201–204.
86. [86] Gheith, O., Sheashaa, H., Abdelsalam, M., Shoeir, Z., Sobh, M., Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Clin Exp Nephrol 12 (2008), 189–194.
87. [87] Li, J.J., Lu, Z.L., Kou, W.R., Chen, Z., Wu, Y.F., Yu, X.H., et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 49 (2009), 947–956.
88. [88] Lin, C.C., Li, T.C., Lai, M.M., Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 153 (2005), 679–686.
89. [89] Venero, C.V., Venero, J.V., Wortham, D.C., Thompson, P.D., Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 105 (2010), 664–666.
90. [90] Hansen, K.E., Hildebrand, J.P., Ferguson, E.E., Stein, J.H., Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165 (2005), 2671–2676.
91. [91] Chen, C., Uang, Y., Wang, S., Yang, J., Lin, C., Interaction between red yeast rice and CYP450 enzymes/P-glycoprotein and its implication for the clinical pharmacokinetics of lovastatin. Evid Based Complement Alternat Med, 2012, 2011, 127043.
92. [92] Sahebkar, A., Serban, C., Ursoniu, S., Banach, M., Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials. Nutrition 32 (2016), 33–40.
93. [93] Warshafsky, S., Kamer, R.S., Sivak, S.L., Effect of garlic on total serum cholesterol: a meta-analysis. Ann Intern Med 119 (1993), 599–605.
94. [94] Silagy, C.A., Neil, H.A., A meta-analysis of the effect of garlic on blood pressure. J Hypertens 12 (1994), 463–468.
95. [95] Stevinson, C., Pittler, M.H., Ernst, E., Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. Ann Intern Med 133 (2000), 420–429.
96. [96] Ackermann, R.T., Mulrow, C.D., Ramirez, G., Gardner, C.D., Morbidoni, L., Lawrence, V.A., Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 161 (2001), 813–824.
97. [97] Khoo, Y., Aziz, Z., Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 34 (2009), 133–145.
98. [98] Reinhart, K.M., Talati, R., White, C.M., Coleman, C.I., The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev 22 (2009), 39–48.
99. [99] Zeng, T., Guo, F.F., Zhang, C.L., Song, F.Y., Zhao, X.L., Xie, K.Q., A meta-analysis of randomized, double-blind, placebo-controlled trials for the effects of garlic on serum lipid profiles. J Sci Food Agric 92 (2012), 1892–1902.
100. [100] Gardner, C.D., Lawson, L.D., Block, E., Chatterjee, L.M., Kiazand, A., Balise, R.R., et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med 167 (2007), 346–353.
101. [101] Liu, L., Yeh, Y.Y., S-alk (en) yl cysteines of garlic inhibit cholesterol synthesis by deactivating HMG-CoA reductase in cultured rat hepatocytes. J Nutr 132 (2002), 1129–1134.
102. [102] Kwon, M.J., Song, Y.S., Choi, M.S., Park, S.J., Jeong, K.S., Song, Y.O., Cholesteryl ester transfer protein activity and atherogenic parameters in rabbits supplemented with cholesterol and garlic powder. Life Sci 72 (2003), 2953–2964.
103. [103] Amagase, H., Clarifying the real bioactive constituents of garlic. J Nutr 136 (2006), 716S–725S.
104. [104] Rahman, K., Lowe, G.M., Garlic and cardiovascular disease: a critical review. J Nutr 136 (2006), 736S–740S.
105. [105] Borriello, A., Bencivenga, D., Caldarelli, I., Tramontano, A., Borgia, A., Zappia, V., et al. Resveratrol: from basic studies to bedside. Cancer Treat Res 159 (2014), 167–184.
106. [106] Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003), 191–196.
107. [107] Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006), 337–342.
108. [108] Chow, H.S., Garland, L.L., Heckman-Stoddard, B.M., Hsu, C.H., Butler, V.D., Cordova, C.A., et al. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J Transl Med, 12, 2014, 223.
109. [109] Witte, A.V., Kerti, L., Margulies, D.S., Flöel, A., Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 34 (2014), 7862–7870.
110. [110] Chachay, V.S., Macdonald, G.A., Martin, J.H., Whitehead, J.P., O'Moore–Sullivan, T.M., Lee, P., et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastoenterol Hepatol 12 (2014), 2092–2103.
111. [111] Liu, Y., Ma, W., Zhang, P., He, S., Huang, D., Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 34 (2015), 27–34.
112. [112] Sahebkar, A., Serban, C., Ursoniu, S., Wong, N.D., Muntner, P., Graham, I.M., et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular parameters: results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 189 (2015), 47–55.
113. [113] Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., et al. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 61 (2013), 215–226.
114. [114] Liu, K., Zhou, R., Wang, B., Mi, M.T., Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 99 (2014), 1510–1519.
115. [115] Mohagheghi, A., Maghsoud, S., Khashayar, P., Ghazi-Khansari, M., The effect of Hibiscus sabdariffa on lipid profile, creatinine, and serum electrolytes: a randomized clinical trial. ISRN Gastroenter, 2011, 2010, 976019.
116. [116] Sindi, H.A., Marshall, L.J., Morgan, M.R., Comparative chemical and biochemical analysis of extracts of Hibiscus sabdariffa. Food Chem 164 (2014), 23–29.
117. [117] Herrera-Arellano, A., Flores-Romero, S., Chavez-Soto, M., Tortoriello, J., Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phytomedicine 11 (2004), 375–382.
118. [118] Herrera-Arellano, A., Miranda-Sánchez, J., Ávila-Castro, P., Herrera-Álvarez, S., Jiménez-Ferrer, J.E., Zamilpa, A., et al. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. Planta Med 73 (2007), 6–12.
119. [119] Hirunpanich, V., Utaipat, A., Morales, N.P., Bunyapraphatsara, N., Sato, H., Herunsale, A., et al. Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats. J Ethnopharmacol 103 (2006), 252–260.
120. [120] Chang, H.C., Peng, C.H., Yeh, D.M., Kao, E.S., Wang, C.J., Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans. Food Funct 5 (2014), 734–739.
121. [121] Serban, C., Sahebkar, A., Ursoniu, S., Andrica, F., Banach, M., Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 33 (2015), 1119–1127.
122. [122] Gould, K.S., McKelvie, J., Markham, K.R., Do anthocyanins function as antioxidants in leaves? Imaging of H2 O2 in red and green leaves after mechanical injury. Plant Cell Environ 25 (2002), 1261–1269.
123. [123] Li, D., Zhang, Y., Liu, Y., Sun, R., Xia, M., A randomized clinical trial evaluating the efficacy of an anthocyanin-maqui berry extract (Delphinol®) on oxidative stress biomarkers. J Nutr 145 (2015), 742–748.
124. [124] Davinelli, S., Bertoglio, J.C., Zarrelli, A., Pina, R., Scapagnini, G., A randomized clinical trial evaluating the efficacy of an anthocyanin-maqui berry extract (Delphinol®) on oxidative stress biomarkers. J Am Coll Nutr 34:suppl 1 (2015), 28–33.
125. [125] Amin, H.P., Czank, C., Raheem, S., Zhang, Q., Botting, N.P., Cassidy, A., et al. Anthocyanins and their physiologically relevant metabolites alter the expression of IL-6 and VCAM-1 in CD40 L and oxidized LDL challenged vascular endothelial cells. Mol Nutr Food Res 59 (2015), 1095–1106.
126. [126] Prakash, D., Gupta, C., Role of antioxidant polyphenols in nutraceuticals and human health. Prakash, D., Gupta, C., (eds.) Phytochemicals of nutraceutical importance, 2014, CABI International Publishers, Wallingford, UK, 208.
127. [127] Jäger, R., Lowery, R.P., Calvanese, A.V., Joy, J.M., Purpura, M., Wilson, J.M., Comparative absorption of curcumin formulations. Nutr J, 13, 2014, 11.
128. [128] Menon, V.P., Sudheer, A.R., Antioxidant and anti-inflammatory properties of curcumin. Aggarwal, B.B., Surh, Y.J., Shishodia, S., (eds.) The molecular targets and therapeutic uses of curcumin in health and disease, 2007, Springer, New York, NY, 105–125.
129. [129] Sahebkar, A., Are curcuminoids effective c-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 28 (2014), 633–642.
130. [130] Sahebkar, A., Mohammadi, A., Atabati, A., Rahiman, S., Tavallaie, S., Iranshahi, M., et al. Curcuminoids modulate pro-oxidant–antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27 (2013), 1883–1888.
131. [131] Sahebkar, A., Serban, M.C., Ursoniu, S., Banach, M., Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J Funct Foods 18:Part B (2015), 898–909.
132. [132] Panahi, Y., Saadat, A., Beiraghdar, F., Hosseini Nouzari, S.M., Jalalian, H.R., Sahebkar, A., Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: a randomized double-blind placebo-controlled trial. J Funct Foods 6 (2014), 615–622.
133. [133] Panahi, Y., Saadat, A., Beiraghdar, F., Sahebkar, A., Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 28 (2014), 1461–1467.
134. [134] Panahi, Y., Sahebkar, A., Amiri, M., Davoudi, S.M., Beiraghdar, F., Hoseininejad, S.L., et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108 (2012), 1272–1279.
135. [135] Panahi, Y., Sahebkar, A., Parvin, S., Saadat, A., A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49 (2012), 580–588.
136. [136] Sahebkar, A., Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94 (2010), e75–e76.
137. [137] Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol, 11, 2014, 123.
138. [138] Zingg, J.M., Hasan, S.T., Meydani, M., Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 39 (2013), 101–121.
139. [139] Sahebkar, A., Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 39 (2013), 197–208.
140. [140] Hasan, S., Zingg, J.M., Kwan, P., Noble, T., Smith, D., Meydani, M., Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 232 (2014), 40–51.
141. [141] Shin, S.K., Ha, T.Y., McGregor, R.A., Choi, M.S., Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 55 (2011), 1829–1840.
142. [142] Um, M.Y., Hwang, K.H., Ahn, J., Ha, T.Y., Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 113 (2013), 152–157.
143. [143] Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22 (2014), 851–857.
144. [144] Yang, Y.S., Su, Y.F., Yang, H.W., Lee, Y.H., Chou, J.I., Ueng, K.C., Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res 28 (2014), 1770–1777.
145. [145] Mohammadi, A., Sahebkar, A., Iranshahi, M., Amini, M., Khojasteh, R., Ghayour-Mobarhan, M., et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27 (2013), 374–379.
146. [146] Yum, H., Jee, S., Chen, G., Chen, T.M., Chen, C., Lai, M.K., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (2001), 2895–2900.
147. [147] Bisht, S., Maitra, A., Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol 6 (2009), 192–199.
148. [148] Dupasquier, C.M., Dibrov, E., Kneesh, A.L., Cheung, P.K., Lee, K.G., Alexander, H.K., et al. Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions. Am J Physiol Heart Circ Physiol 293 (2007), H2394–H2402.
149. [149] Caligiuri, S.P., Aukema, H.M., Ravandi, A., Pierce, G.N., Elevated levels of pro-inflammatory oxylipins in older subjects are normalized by flaxseed consumption. Exp Gerontol 59 (2014), 51–57.
150. [150] Ursoniu, S., Sahebkar, A., Andrica, F., Serban, C., Banach, M., Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trial. Clin Nutr 35 (2016), 615–625.
151. [151] Wang, Z.M., Zhou, B., Wang, Y.S., Gong, Q.Y., Wang, Q.M., Yan, J.J., et al. Black and green tea consumption and the risk of coronary artery disease: a meta-analysis. Am J Clin Nutr 93 (2011), 506–515.
152. [152] Islam, M.A., Cardiovascular effects of green tea catechins: progress and promise. Recent Pat Cardiovasc Drug Discov 7 (2012), 88–99.
153. [153] Serban, C., Sahebkar, A., Antal, D., Ursoniu, S., Banach, M., Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Nutrition 31 (2015), 1061–1071.
154. [154] Rains, T.M., Agarwal, S., Maki, K.C., Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem 22 (2011), 1–7.
155. [155] Keske, M., Ng, H., Premilovac, D., Rattigan, S., Kim, J., Munir, K., et al. Vascular and metabolic actions of the green tea polyphenol epigallocatechin gallate. Curr Med Chem 22 (2015), 59–69.
156. [156] Zheng, X.X., Xu, Y.L., Li, S.H., Liu, X.X., Hui, R., Huang, X.H., Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr 94 (2011), 601–610.
157. [157] Shishikura, Y., Khokhar, S., Murray, B.S., Effects of tea polyphenols on emulsification of olive oil in a small intestine model system. J Agric Food Chem 54 (2006), 1906–1913.
158. [158] Lu, C.H., Hwang, L.S., Polyphenol contents of Pu-Erh teas and their abilities to inhibit cholesterol biosynthesis in Hep G2 cell line. Food Chem 111 (2008), 67–71.
159. [159] Singh, D.K., Banerjee, S., Porter, T.D., Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells. J Nutr Biochem 20 (2009), 816–822.
160. [160] Cuccioloni, M., Mozzicafreddo, M., Spina, M., Tran, C.N., Falconi, M., Eleuteri, A.M., et al. Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase. J Lipid Res 52 (2011), 897–907.
161. [161] Puig, T., Relat, J., Marrero, P.F., Haro, D., Brunet, J., Colomer, R., Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res 28 (2008), 3671–3676.
162. [162] Way, T.D., Lin, H.Y., Kuo, D.H., Tsai, S.J., Shieh, J.C., Wu, J.C., et al. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem 57 (2009), 5257–5264.
163. [163] Bursill, C.A., Roach, P.D., A green tea catechin extract upregulates the hepatic low-density lipoprotein receptor in rats. Lipids 42 (2007), 621–627.
164. [164] Annaba, F., Kumar, P., Dudeja, A.K., Saksena, S., Gill, R.K., Alrefai, W.A., Green tea catechin EGCG inhibits ileal apical sodium bile acid transporter ASBT. Am J Physiol Gastrointest Liver Physiol 298 (2010), G467–G473.
165. [165] Samman, S., Sandström, B., Toft, M.B., Bukhave, K., Jensen, M., Sørensen, S.S., et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J Clin Nutr 73 (2001), 607–612.
166. [166] Shiraishi, M., Haruna, M., Matsuzaki, M., Ota, E., Murayama, R., Murashima, S., Association between the serum folate levels and tea consumption during pregnancy. Biosci Trends 4 (2010), 225–230.
167. [167] Alemdaroglu, N.C., Dietz, U., Wolffram, S., Spahn-Langguth, H., Langguth, P., Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm Drug Dispos 29 (2008), 335–348.
168. [168] Mazokopakis, E.E., Starakis, I.K., Papadomanolaki, M.G., Mavroeidi, N.G., Ganotakis, E.S., The hypolipidaemic effects of spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric 94 (2014), 432–437.
169. [169] Mazokopakis, E.E., Karefilakis, C.M., Tsartsalis, A.N., Milkas, A.N., Ganotakis, E.S., Acute rhabdomyolysis caused by spirulina (Arthrospira platensis). Phytomedicine 15 (2008), 525–527.
170. [170] Lee, E.H., Park, J.E., Choi, Y.J., Huh, K.B., Kim, W.Y., A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients. Nutr Res Pract 2 (2008), 295–300.
171. [171] Parikh, P., Mani, U., Iyer, U., Role of spirulina in the control of glycemia and lipidemia in type 2 diabetes mellitus. J Med Food 4 (2001), 193–199.
172. [172] Park, H.J., Lee, Y.J., Ryu, H.K., Kim, M.H., Chung, H.W., Kim, W.Y., A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans. Ann Nutr Metab 52 (2008), 322–328.
173. [173] Ramamoorthy, A., Premakumari, S., Effect of supplementation of spirulina on hypercholesterolemic patients. J Food Sci Technol 33 (1996), 124–127.
174. [174] Anitha, L., Chandralekha, K., Effect of supplementation of spirulina on blood glucose, glycosylated hemoglobin and lipid profile of male non-insulin dependent diabetics. Asian J Exp Biol Sci 1 (2010), 36–46.
175. [175] Samuels, R., Mani, U., Iyer, U., Nayak, U., Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome. J Med Food 5 (2002), 91–96.
176. [176] Nagaoka, S., Shimizu, K., Kaneko, H., Shibayama, F., Morikawa, K., Kanamaru, Y., et al. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of spirulina platensis concentrate in rats. J Nutr 135 (2005), 2425–2430.
177. [177] Salazar, M., Martınez, E., Madrigal, E., Ruiz, L., Chamorro, G., Subchronic toxicity study in mice fed Spirulina maxima. J Ethnopharmacol 62 (1998), 235–241.
178. [178] Belay, A., The potential application of spirulina (Arthrospira) as a nutritional and therapeutic supplement in health management. JANA 5 (2002), 27–48.
179. [179] Tarantino LM. Agency Response Letter GRAS Notice No. GRN 000127. Available at: http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm153944.htm. Accessed May 22, 2016.
180. [180] Pereira, S.L., Leonard, A.E., Huang, Y.S., Chuang, L.T., Mukerji, P., Identification of two novel microalgal enzymes involved in the conversion of the ω3-fatty acid, eicosapentaenoic acid, into docosahexaenoic acid. Biochem J 384 (2004), 357–366.
181. [181] Fares, H., Lavie, C.J., DiNicolantonio, J.J., O'Keefe, J.H., Milani, R.V., Omega-3 fatty acids: a growing ocean of choices. Curr Atheroscler Rep 16 (2014), 1–12.
182. [182] Kuratko, C.N., Nolan, C.C., Salem, N. Jr., Long–chain omega-3 fatty acids and cardiovascular health. Nutrafoods 13 (2014), 49–60.
183. [183] Fish oil supplements. JAMA 312 (2014), 839–840.
184. [184] Hegele, R.A., Ginsberg, H.N., Chapman, M.J., Nordestgaard, B.G., Kuivenhoven, J.A., Averna, M., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2 (2014), 655–666.
185. [185] Dietary Guidelines Advisory Committee. Report of the Dietary Guidelines Advisory Committee on the Dietary Guidelines for Americans, 2010, to the Secretary of Agriculture and the Secretary of Health and Human Services. Agricultural Research Service. Available at: http://www.nutriwatch.org/05Guidelines/dga_advisory_2010.pdf. Accessed May 22, 2016.
186. [186] Lloyd-Jones, D.M., Hong, Y., Labarthe, D., Mozaffarian, D., Appel, L.J., Van Horn, L., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction the American Heart Association's Strategic Impact Goal through 2020 and beyond. Circulation 121 (2010), 586–613.
187. [187] Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11 (2014), 506–514.
188. [188] Taibi, A., Comelli, E.M., Practical approaches to probiotics use. Appl Physiol Nutr Metab 39 (2014), 980–986.
189. [189] Ivey, K.L., Hodgson, J.M., Kerr, D.A., Thompson, P.L., Stojceski, B., Prince, R.L., The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial. Nutr Metab Cardiovasc Dis 25 (2015), 46–51.
190. [190] Didari, T., Solki, S., Mozaffari, S., Nikfar, S., Abdollahi, M., A systematic review of the safety of probiotics. Expert Opin Drug Saf 13 (2014), 227–239.
191. [191] Mitchell, P.L., McLeod, R.S., Conjugated linoleic acid and atherosclerosis: studies in animal models. Biochem Cell Biol 86 (2008), 293–301.
192. [192] Mooney, D., McCarthy, C., Belton, O., Effects of conjugated linoleic acid isomers on monocyte, macrophage and foam cell phenotype in atherosclerosis. Prostaglandins Other Lipid Mediat 98 (2012), 56–62.
193. [193] Castro-Webb, N., Ruiz-Narvaez, E.A., Campos, H., Cross-sectional study of conjugated linoleic acid in adipose tissue and risk of diabetes. Am J Clin Nutr 96 (2012), 175–181.
194. [194] Wang, Y.W., Jones, P.J., Conjugated linoleic acid and obesity control: efficacy and mechanisms. Int J Obes Relat Metab Disord 28 (2004), 941–955.
195. [195] Bialek, A., Tokarz, A., Conjugated linoleic acid as a potential protective factor in prevention of breast cancer. Postepy Hig Med Dosw 67 (2013), 6–14.
196. [196] Heinze, V.M., Actis, A.B., Dietary conjugated linoleic acid and long-chain n-3 fatty acids in mammary and prostate cancer protection: a review. Int J Food Sci Nutr 63 (2012), 66–78.
197. [197] Gholami, Z., Khosravi-Darani, K., An overview of conjugated linoleic acid: microbial production and application. Mini Rev Med Chem 14 (2014), 734–746.
198. [198] Watkins, B.A., Seifert, M.F., Conjugated linoleic acid and bone biology. J Am Coll Nutr 19 (2000), 478S–486S.
199. [199] Whigham, L.D., Watras, A.C., Schoeller, D.A., Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr 85 (2007), 1203–1211.
200. [200] Miranda, J., Arias, N., Fernández-Quintela, A., del Puy Portillo, M., Are conjugated linolenic acid isomers an alternative to conjugated linoleic acid isomers in obesity prevention?. Endocrinol Nutr 61 (2014), 209–219.
201. [201] López-Barrios, L., Gutiérrez-Uribe, J.A., Serna-Saldívar, S.O., Bioactive peptides and hydrolysates from pulses and their potential use as functional ingredients. J Food Sci 79 (2014), R273–R283.
202. [202] US Department of Agriculture and Health and Human Services. Dietary guidelines for Americans. 2010, US Government Printing Office, Washington, DC.
203. [203] Friedman, M., Juneja, V.K., Review of antimicrobial and antioxidative activities of chitosans in food. J Food Prot 73 (2010), 1737–1761.
204. [204] Rizzo, M., Giglio, R.V., Nikolic, D., Patti, A.M., Campanella, C., Cocchi, M., et al. Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. Angiology 65 (2014), 538–542.
205. [205] Mhurchu, C.N., Poppitt, S., McGill, A., Leahy, F., Bennett, D., Lin, R., et al. The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes 28 (2004), 1149–1156.
206. [206] Rahar, S., Swami, G., Nagpal, N., Nagpal, M.A., Singh, G.S., Preparation, characterization, and biological properties of β-glucans. J Adv Pharm Technol Res, 2, 2011, 94.
207. [207] Wolever, T.M., Tosh, S.M., Gibbs, A.L., Brand-Miller, J., Duncan, A.M., Hart, V., et al. Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. Am J Clin Nutr 92 (2010), 723–732.
208. [208] Kerckhoffs, D.A., Hornstra, G., Mensink, R.P., Cholesterol-lowering effect of β-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when β-glucan is incorporated into bread and cookies. Am J Clin Nutr 78 (2003), 221–227.
209. [209] Reiner, Z., Catapano, A., De Backer, G., Graham, I., Taskinen, M., Wiklund, O., et al. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 32 (2011), 1769–1818.
210. [210] Cleeman, J., Grundy, S., Becker, D., Clark, L., Expert panel on Detection, Evaluation and Treatment of High blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). JAMA 285 (2001), 2486–2497.
211. [211] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J, 8, 2010, 188.
212. [212] Sood, N., Baker, W.L., Coleman, C.I., Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr 88 (2008), 1167–1175.
213. [213] Onakpoya, I., Posadzki, P., Ernst, E., The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr 33 (2014), 70–78.
214. [214] Keithley, J., Swanson, B., Glucomannan and obesity: a critical review. Altern Ther Health Med, 11, 2005, 30.
215. [215] Serban, M.C., Banach, M., Mikhailidis, D.P., Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother 17 (2016), 369–380.
216. [216] Chruściel, P., Mikhailidis, D., Toth, P., Rysz, J., Banach, M., Statins and fibrates: should they be recommended?. Banach, M., (eds.) Combination therapy in dyslipidemia, 2015, Springer International Publishing, Cham, Switzerland, 11–23.
217. [217] Hobbs, F.D., Banach, M., Mikhailidis, D.P., Malhotra, A., Capewell, S., Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med, 14, 2016, 4.
218. [218] Banach, M., Aronow, W.S., Serban, M.C., Rysz, J., Voroneanu, L., Covic, A., Lipids, blood pressure and kidney update 2015. Lipids Health Dis, 14, 2015, 167.
219. [219] Michalska-Kasiczak, M., Sahebkar, A., Mikhailidis, D.P., Rysz, J., Muntner, P., Toth, P.P., et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia—A systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 178 (2015), 111–116.
220. [220] Banach, M., Serban, C., Sahebkar, A., Ursoniu, S., Rysz, J., Muntner, P., et al. Effects of coenzyme Q10 on statin-induced myopathy. Mayo Clin Proc 90 (2015), 24–34.
221. [221] Banach, M., Rizzo, M., Toth, P.P., Farnier, M., Davidson, M.H., Al-Rasadi, K., et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf 14 (2015), 935–955.
222. [222] Banach, M., Serban, C., Ursoniu, S., Rysz, J., Muntner, P., Toth, P.P., et al. Statin therapy and plasma coenzyme Q10 concentrations—a systematic review and meta-analysis of placebo-controlled trials. Pharm Res 99 (2015), 329–336.
223. [223] Banach, M., Rizzo, M., Toth, P.P., Farnier, M., Davidson, M.H., Al-Rasadi, K., et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11 (2015), 1–23.